Julie Yu

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

Dominique P. Germain, Derralynn Hughes, Daniel G. Bichet et al. · New England Journal of Medicine · 2016 · 535 citations · Full text

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

Zhi‐Wei Lai, Ryan L. Kelly, Thomas Winans et al. · The Lancet · 2018 · 390 citations

Rheumatology, Autoimmune Disease, Systemic Lupus Erythematosus Treatment +9

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Derralynn Hughes, Suma P. Shankar, Gere Sunder‐Plassmann et al. · Journal of Medical Genetics · 2016 · 370 citations · Full text

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

Elfrida R. Benjamin, Maria Cecilia Della Valle, Xiaoyang Wu et al. · Genetics in Medicine · 2016 · 207 citations · Full text

Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder

Thomas Hermanns, Bimal Bhindi, Yanliang Wei et al. · British Journal of Cancer · 2014 · 106 citations · Full text